Photocure ASA (PHCUF)
| Previous Close | 5.95 |
| Open | 5.95 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 5.95 - 5.95 |
| 52 Week Range | 4.21 - 10.85 |
| Volume | |
| Avg. Volume | 3 |
| Market Cap | 161.279M |
| Beta (5Y Monthly) | 0.89 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.11 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | May 23, 2013 |
| 1y Target Est | N/A |
PR NewswireEuropean Association of Urology (EAU) 2024 congress features new data on modern technology use in bladder cancer care
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces its participation in the congress, and two abstract presentations at the 2024 European Association of Urology congress (EAU) in Paris, France, highlighting the benefits of Blue Light Cystoscopy (BLC®) in Bladder Cancer management.
PR NewswirePhotocure to Participate in the 23rd Annual Needham Virtual Healthcare Conference
Photocure ASA (OSE: PHO), The Bladder Cancer Company, announces that President and Chief Executive Officer, Dan Schneider will present a corporate overview and host 1-on-1 meetings with investors at the 23rd Annual Needham Healthcare Conference being held virtually April 8-11, 2024.
PR NewswireNew Publication: Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy
Photocure ASA, The Bladder Cancer Company, announces the publication of the study "Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry" in the journal Cancers this week. This study aims to evaluate heterogeneity in characteristics of blue light cystoscopy (BLC®) for detection of malignant lesions among various races with non-muscle invasive bladder cancer (NMIBC).
